Filtered By:
Specialty: Research
Condition: Atrial Fibrillation

This page shows you your search results in order of date. This is page number 12.

Order by Relevance | Date

Total 257 results found since Jan 2013.

Comparative effectiveness and safety of non-vitamin k antagonist oral anticoagulants and warfarin in older adults with atrial fibrillation and diabetes.
CONCLUSION: Oral anticoagulation therapy with NOACs was found to be more effective than warfarin therapy among older adults with NVAF and comorbid DM. PMID: 33327796 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Impact of prescription patterns of antithrombotic treatment on atrial fibrillation-related ischemic stroke.
CONCLUSIONS: The prescription of oral anticoagulants, particularly direct oral anticoagulants, has increased from 2013 to 2019 in our Health Assistance Area. This increase might partially explain the reduction in AF-related IS. PMID: 33326304 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - December 18, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Do We Need to Distinguish Thrombolysis and Nonthrombolysis Patients When Applying Stroke-Associated Pneumonia Predicting Scores? An External Validation from a 2-Center Database.
CONCLUSIONS The AIS-APS had the highest AUC and goodness of fit in our population. All 4 scores can be applied regardless of whether thrombolysis has been performed on patients. PMID: 32921786 [PubMed - in process]
Source: Medical Science Monitor - September 15, 2020 Category: Research Tags: Med Sci Monit Source Type: research

Detection of arrhythmia using an implantable cardiac monitor following a cryptogenic stroke: a single-center observational study
ConclusionsThis study confirmed the feasibility of using an interdisciplinary and intersectoral therapeutic approach for monitoring CS patients with implanted ICMs. Further randomized studies are warranted to confirm these encouraging data. An open discussion concerning optimal care forms and opportunities for introducing digitizing care pathways appears warranted.
Source: European Journal of Medical Research - June 28, 2020 Category: Research Source Type: research

Practical challenges in the conduct of pragmatic trials embedded in health plans: Lessons of IMPACT-AFib, an FDA-Catalyst trial.
Abstract IMPACT-AFib was an 80,000-patient randomized clinical trial implemented by five US insurance companies (health plans) aimed at increasing the use of oral anticoagulants by individuals with atrial fibrillation who were at high risk of stroke and not on treatment. The underlying thesis was that patients could be change agents to initiate prescribing discussions with their providers. We tested the effect of mailing information to both patients and their providers. We used administrative medical claims and pharmacy dispensing data to identify eligible patients, to randomize them to an early or delayed interve...
Source: Clinical Trials - June 25, 2020 Category: Research Authors: Garcia CJ, Haynes K, Pokorney SD, Lin ND, McMahill-Walraven C, Nair V, Parlett L, Martin D, Al-Khalidi HR, McCall D, Granger CB, Platt R, Cocoros NM Tags: Clin Trials Source Type: research

Minor bleeding in patients with atrial fibrillation using a non-vitamin K antagonist oral anticoagulant.
Conclusion: Our data showed that minor bleeds are common in novel NOAC users, especially when using apixaban and rivaroxaban. In the latter two NOACs, hematoma (bruises) and nose bleeds were more frequently observed and accounted for the difference with dabigatran. Besides type of NOAC, a higher HAS-BLED score and novel anticoagulant drug use were associated with an increased risk of minor bleeding. PMID: 32573287 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - June 24, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation
To demonstrate how the Observational Healthcare Data Science and Informatics (OHDSI) collaborative network and standardization can be utilized to scale-up external validation of patient-level prediction models...
Source: BMC Medical Research Methodology - May 6, 2020 Category: Research Authors: Jenna M. Reps, Ross D. Williams, Seng Chan You, Thomas Falconer, Evan Minty, Alison Callahan, Patrick B. Ryan, Rae Woong Park, Hong-Seok Lim and Peter Rijnbeek Tags: Research article Source Type: research

Effectiveness and Safety of Rivaroxaban Versus Warfarin in Obese Nonvalvular Atrial Fibrillation Patients: Analysis of Electronic Health Record Data.
Conclusions: Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes. PMID: 32347755 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - May 1, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia.
CONCLUSIONS: Heterozygous FH is associated with increased risk for stroke, PAD and AoVC. Clinicians should take these non-CHD ASCVD aspects into consideration for optimal management of FH patients. PMID: 32096673 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 27, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Reasons for discontinuation of novel oral anticoagulant therapy in patients with atrial fibrillation.
Conclusion: DOAC discontinuation rates varied significantly and appeared related to drug-specific side effects, patient-initiated discontinuation, and bleeding. We observed longer-term administration of apixaban, suggesting that this drug is better tolerated than dabigatran or rivaroxaban. PMID: 32011180 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - February 5, 2020 Category: Research Tags: Curr Med Res Opin Source Type: research

Ablation Versus Medical Therapy for Atrial Fibrillation in the Elderly: A Propensity Score-Matched Comparison.
CONCLUSIONS In this propensity-matched elderly sample, ablation therapy was associated with lower risk of composite outcome consisting of all-cause death, non-fatal stroke, and peripheral embolism, and therefore might be an alternative to conservative therapy. PMID: 31866666 [PubMed - in process]
Source: Medical Science Monitor - December 25, 2019 Category: Research Tags: Med Sci Monit Source Type: research

Sex Differences in Presentation, Quality of Life, and Treatment in Chinese Atrial Fibrillation Patients: Insights from the China Atrial Fibrillation Registry Study.
CONCLUSIONS</strong> In Chinese AF patients, women were older and more symptomatic, and had worse QoL. Despite all these differences, women tended to receive less rhythm-control treatment in those aged <75 years. Oral anticoagulant was substantially underused in high stroke risk patients, regardless of sex. PMID: 31738742 [PubMed - in process]
Source: Medical Science Monitor - November 21, 2019 Category: Research Tags: Med Sci Monit Source Type: research

RE-LY-trial-publication-10-year-anniversary
Anniversary of the pivotal RE-LY ® trial marks a decade of innovation for stroke prevention in AF patients10 years ago, RE-LY ® marked the first time a randomised trial showed that a non-vitamin K antagonist oral anticoagulant (NOAC) was safer and at least as effective as warfarin for stroke prevention in atrial fibrillation (SPAF)1-3First major scientific advancement in anticoagulation care in over fifty yearsOver 100,000 patients have been included in the RE-VOLUTION study programme worldwide,4 and research into dabigatran etexilate continues
Source: Boehringer Ingelheim Corporate News - August 30, 2019 Category: Research Source Type: news

Early prolonged ambulatory cardiac monitoring in stroke (EPACS): an open-label randomised controlled trial
ConclusionsEarly, prolonged, patch-based monitoring after an index stroke or TIA is superior to short-duration Holter monitoring in the detection of PAF and likely cost-effective for preventing recurrent strokes.Trial registrationhttp://www.isrctn.com. Unique identifier: ISRCTN 50253271. Registered 21 January 2016
Source: European Journal of Medical Research - July 25, 2019 Category: Research Source Type: research

Real-life behaviour of direct oral anticoagulants in a Spanish cohort with nonvalvular atrial fibrillation: Refase Registry.
CONCLUSION: Our results of safety and efficacy are very similar to those of other previously published national registries. There were no differences among the different types of DOAC regarding outcomes. However, it was found that people taking the adjusted dose of the drug seemed to have a higher risk of death. A non-negligible proportion of patients received DOAC doses inconsistent with labelling (mostly underdose). PMID: 31335222 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - July 25, 2019 Category: Research Tags: Curr Med Res Opin Source Type: research